The agricultural revolution of the Neolithic era transformed this relationship. As humans settled into wetlands rich in natural resources and began cultivating crops and domesticating cattle, pigs, sheep, and goats, meat consumption became more predictable but also more constrained. Livestock represented long-term investments, and the meaning of meat shifted from opportunistic game to managed capital. Archaeological studies reveal that this dietary transition came at a cost: overall protein intake declined, human height decreased from the Paleolithic to the Neolithic, and conditions such as osteomalacia, dental cavities, and malnutrition became more prevalent among populations reliant on high-carbohydrate, low-protein diets. Meat also became embedded in ritual, hierarchy, and identity, with slaughter ceremonies and distribution patterns reflecting social stratification in early agrarian societies.

Throughout the Middle Ages and into the Industrial Revolution, meat remained a marker of class and power. Livestock served primarily as sources of labor, dairy, wool, and leather, and most ordinary people rarely ate fresh meat. After the Black Death devastated the labor force in the fourteenth century, landowners expanded livestock breeding for profit, and a growing rural economy increasingly depended on animals. Scientific advances in forage production, selective breeding, and animal husbandry, together with urbanization and mercantilism, gradually increased supply. The Industrial Revolution mechanized slaughtering and butchering, turning meat processing from a small craft into a science-based industry dominated by sausages, bacon, and canned products. By the twentieth century, vaccines, optimized feed formulas, and global cold-chain logistics had made meat a daily staple in many developed nations.

Today, however, that industrial success has collided with serious global challenges. The Food and Agriculture Organization projects that the world population will reach 9.73 billion by 2050, driving continued growth in demand for animal protein even as livestock production accounts for an estimated 14 to 21 percent of total anthropogenic greenhouse gas emissions, primarily methane from enteric fermentation and manure management. Public health debates, including the controversy over red and processed meat consumption, animal welfare concerns about factory farming, and consumer shifts toward vegetarian and flexitarian diets, have intensified pressure on conventional producers. A new review by Dongheon Lee and Cheorun Jo of Seoul National University, published in Food Science of Animal Resources, argues that the industry must respond with technological innovation rather than incremental change, and it maps out the most promising avenues now under development.

Among the most transformative of these is the application of artificial intelligence and hyperspectral imaging to meat quality assessment. Hyperspectral imaging captures both spatial and spectral information simultaneously, collecting wavelengths from the visible range of 400 to 750 nanometers into the near-infrared and mid-infrared regions up to 25,000 nanometers. The spectral signatures reflect molecular changes, such as the vibration and stretching of C-H, O-H, and N-H bonds from moisture, amides, and lipids, and even the fluorescence of NADH produced during microbial and endogenous enzyme activity. Machine learning and deep learning algorithms, including partial least squares regression, support vector machines, and convolutional neural networks, are then trained on these data to predict freshness, amino acid content, lipid oxidation, and sensory attributes such as saltiness, fatness, and umami taste. Researchers have even developed smartphone applications equipped with artificial neural networks that allow consumers and suppliers to estimate beef tenderness from a simple image, suggesting a future where quality evaluation is democratized across the supply chain.

Complementing these imaging technologies, metabolomics of meat exudates offers a non-invasive route to quality prediction. Nucleotide-related metabolites derived from ATP degradation and amines such as tyramine, produced by microbial metabolism, correlate strongly with conventional spoilage indicators like pH, volatile basic nitrogen, and total bacterial counts. Models built on drip metabolites have successfully predicted freshness in packaged chicken and pork loin, while metabolomic profiling also reveals flavor precursors that determine palatability. At the farm level, smart livestock farming integrates the Internet of Things, digital sensors, wireless networks, robotics, and artificial intelligence into a three-step process of data acquisition, AI-assisted decision-making, and autonomous execution. Studies have demonstrated the power of this approach in practice: deep learning algorithms paired with closed-circuit television networks have accurately identified known and newly introduced Hanwoo cattle, while convolutional neural network models have detected anemia in small ruminants to optimize parasite management. Precision feeding systems further tailor nutrient delivery to individual animals, improving economics and animal welfare simultaneously.

Genomic technologies represent perhaps the most radical intervention in conventional meat production. Tools such as CRISPR/Cas9, zinc-finger nucleases, transcription activator-like effector nucleases, and base editing enable rapid introduction of genetic variation that would take generations through traditional breeding. Researchers have produced avian leukosis virus-resistant chickens, PRRS virus-resistant pigs, and mycobacterium-resistant cattle, reducing reliance on antibiotics and addressing antimicrobial resistance concerns. Knocking out the myostatin gene, a negative regulator of skeletal muscle growth, improves growth performance and meat quality traits including pH, shear force, and intramuscular fat content. Insertion of the heat-tolerance gene SLICK from Senepol cattle into Holstein genomes enhances thermoregulation, while editing of genes such as IGF2, MyoD1, and fat-1 targets cell proliferation, differentiation, and the conversion of n-6 to n-3 polyunsaturated fatty acids. Yet public acceptance, inconsistent regulation across countries, and concerns about off-target effects remain significant barriers, prompting a shift toward safer, more precise base and prime editing platforms.

Climate resilience is another critical frontier. Strategies include installing shade infrastructure and irrigation, adjusting feeding regimes to cooler times of day with electrolytes and heat-tolerant forages, and selective breeding for thermotolerance. Dietary manipulation offers a powerful mitigation tool: upcycling food wastes, by-products, and insect-based proteins into livestock feed reduces global feed demand and alleviates food-feed competition, while supplementation with dietary oils and phytochemicals has been shown to decrease enteric methane emissions. Interestingly, research on climate adaptation has concentrated heavily on ruminants, leaving a significant gap for non-ruminants such as chickens and pigs, whose meat consumption is comparable or higher in many countries. Small-scale farmers who cannot afford costly adaptation infrastructure may also switch to heat- and water-tolerant species such as goats and donkeys, although the review’s authors note this is a coping strategy rather than a fundamental solution.

Beyond improving conventional production, the review highlights cellular agriculture as a complementary paradigm. Cell-based food, also known as cultivated or cultured meat, is produced by isolating animal stem cells, proliferating them in nutrient-rich media, differentiating them into muscle fibers, adipocytes, or connective tissues, and scaffolding them to create structured products. The field has moved remarkably fast: the first 100-gram beef patty, unveiled by Mark Post’s team in the Netherlands in 2013, cost roughly $330,000 to produce, but the price of a cell-based patty had dropped to $11.36 within four years, and the cost of chicken patty production has now fallen below $1,190 per kilogram. Singapore approved the first commercial cell-based products in 2020, the United States followed in 2023, and Israel and Hong Kong granted approval in 2024. In 2025, the FDA approved the first cell-based fat and cultivated salmon products for commercialization. Key research priorities now include serum-free media development to eliminate fetal bovine serum, edible and biodegradable scaffold materials, vascularization strategies to deliver oxygen and nutrients in dense tissues, and co-culture of muscle and fat cells to reproduce marbling and flavor complexity.

Precision fermentation and hybrid cell-based foods round out the emerging protein landscape. Precision fermentation uses genetically engineered yeasts and fungi to produce heme proteins, structural proteins, enzymes, lipids, and flavorings that are functionally identical to their animal-derived counterparts, enhancing the color, flavor, and nutrition of meat alternatives. Hybrid cell-based foods blend animal, plant, and microbial components, with plant proteins typically comprising 20 to 50 percent of formulations to exploit their biocompatibility and structural flexibility, while mycelium-based ingredients add dietary fiber, phenolic compounds, and antioxidant capacity. The authors emphasize that these technologies will not replace conventional meat but rather complement it in a mixed-model food system. Conventional meat retains advantages in sensory richness, nutritional value, and cultural familiarity, while cell-based and plant-based alternatives address sustainability, ethics, and resource efficiency. Consumer acceptance remains the decisive variable: food neophobia, price expectations, and perceived unnaturalness are the principal obstacles, though studies show that transparent scientific information and safety assurance can significantly reduce skepticism. As Lee and Jo conclude, the future of meat will depend on how thoughtfully and responsively we innovate its production, with meat science expanding into a multidisciplinary endeavor that integrates biotechnology, tissue engineering, artificial intelligence, and synthetic biology to build resilient and sustainable food systems.

Subject of Research: Innovations in meat production technologies and cellular agriculture for sustainable food systems

Article Title: The future of meat: innovations in production within an expanding and sustainable food system

Article References: Lee, D., & Jo, C. (2026). The future of meat: innovations in production within an expanding and sustainable food system. Food Science of Animal Resources, 46(1), Article 93. https://doi.org/10.1007/s44463-026-00079-4

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00079-4

Keywords: meat production, cellular agriculture, cultivated meat, hyperspectral imaging, artificial intelligence, smart livestock farming, CRISPR gene editing, climate resilience, greenhouse gas emissions, precision fermentation, hybrid meat products, food sustainability

Neuronal intranuclear inclusion disease is a rare but severe condition notable for its heterogeneous symptomatology including cognitive decline, motor dysfunction, peripheral neuropathy, and autonomic disturbances. Central to the disease’s molecular pathology is the aberrant elongation of GGC trinucleotide repeats within the 5’ untranslated region of the NOTCH2NLC gene. These expanded repeats trigger toxic gain-of-function mechanisms, fostering accumulation of intranuclear inclusions that disrupt normal neuronal physiology and provoke cell death. Prior treatments have been limited to symptomatic management as no approach existed to rectify the genetic root cause.

Harnessing the exquisite specificity of the CRISPR/Cas9 gene editing system, the researchers designed guide RNAs strategically flanking the repeat expansions, enabling precise double-strand breaks that excise the aberrant GGC repeat sequences. This excision restores normal genomic architecture without disrupting the surrounding functional elements of NOTCH2NLC, a crucial consideration for maintaining gene regulatory integrity. Through rigorous validation in patient-derived cell models and sophisticated in vivo systems, the approach demonstrated efficient, targeted removal of the repeats, substantially reducing cellular toxicity and normalizing gene expression profiles.

This innovative approach leverages advances in genome engineering that allow for highly localized DNA editing, minimizing off-target effects that have historically tempered the clinical translation of CRISPR technologies. The team utilized deep sequencing techniques and advanced bioinformatics to meticulously confirm the precision and fidelity of the excision events, assuring the safety and efficacy profile required for therapeutic applications. Notably, no large-scale chromosomal rearrangements or unintended mutations were detected, underscoring the method’s robustness.

In addition to mechanistic insights, the study illuminates the therapeutic potential of repeat excision in halting or reversing neurodegeneration. Functional assays revealed restoration of neuronal phenotypes previously impaired by toxic inclusions, including improved mitochondrial function, reduced oxidative stress, and normalization of synaptic markers. Moreover, longitudinal assessments in animal models recapitulated improved motor coordination and cognitive performance, heralding transformative implications for patient quality of life.

Beyond the immediate application to NIID, this breakthrough exemplifies a paradigm for tackling repeat expansion disorders at large—a category that includes Huntington’s disease, fragile X syndrome, and myotonic dystrophy among others. By refining the art of excising pathological genomic sequences, the approach circumvents the complications of gene silencing strategies and offers a permanent genetic remedy. It paves a new avenue wherein genetic medicine transitions from palliative care to true molecular cure.

The meticulous optimization of CRISPR components tailored to the NOTCH2NLC GGC repeat locus was pivotal. The researchers overcame challenges related to the complex secondary DNA structures formed by repeat expansions that often hamper editing efficiency. Through iterative guide RNA design and Cas9 variant testing, they achieved a balance of high editing activity with negligible cytotoxicity. These technical innovations establish a blueprint for future repeat targeting endeavors across diverse genetic landscapes.

Furthermore, the deployment of patient-derived induced pluripotent stem cells (iPSCs) enabled personalized modeling of the disease and direct testing of therapeutic efficacy in a human genetic background. Edited iPSC-derived neurons exhibited a marked disappearance of intranuclear inclusions and restoration of transcriptomic homeostasis, validating the clinical translatability of the strategy. Such patient-tailored platforms could accelerate drug development and regulatory approval pathways in precision neurology.

The study also delves into the broader implications of NOTCH2NLC function in neural development and homeostasis, highlighting that careful excision preserves physiological gene activity while eliminating pathological expansions. This balance is crucial since NOTCH2NLC plays roles in neurogenesis and cell signaling. The authors’ nuanced understanding of gene regulation nuances underscores the sophistication required to safely manipulate complex neurogenetic loci.

In light of these promising results, the research team advocates for progressing toward early-phase clinical trials, emphasizing stringent monitoring of off-target genomic changes and immune responses to CRISPR components. They also foresee integrating delivery modalities optimized for central nervous system penetration, such as viral vectors and nanoparticle carriers, to effectively reach affected neuronal populations in patients.

Ethical considerations surrounding germline editing and long-term follow-up are extensively discussed, underscoring the responsible stewardship of powerful gene editing technologies. The potential to eradicate a devastating neurodegenerative disease fuels optimism tempered by rigorous scientific and ethical standards to ensure patient safety and societal trust.

This work sets a landmark precedent in the quest to conquer repeat expansion neurodegenerative diseases through precise genomic surgery. By excising the offending DNA sequences themselves rather than merely modulating downstream effects, the authors have articulated a compelling vision of curative gene therapy. The scientific community and patient advocates alike are lauding this innovation as a harbinger of an era where devastating inherited neurological disorders become editable and ultimately eradicated.

As the field advances, the research highlights the critical role of multidisciplinary collaboration spanning molecular genetics, neurobiology, bioinformatics, and clinical sciences in transforming groundbreaking molecular insights into lifesaving interventions. Ultimately, the study embodies the transformative potential of CRISPR/Cas9 not only to rewrite DNA but to rewrite destinies, offering tangible hope to individuals impacted by currently untreatable neurodegenerative conditions.

By laying the foundation for precise, safe, and effective repeat excision therapeutics, this breakthrough marks a seminal achievement poised to redefine the trajectory of gene therapy for complex neurological disorders. Future efforts will undoubtedly expand upon this by refining delivery systems, enhancing editing precision, and broadening the repertoire of targetable genetic lesions, propelling the frontier of genomic medicine into new dimensions. The promise illuminated here shines as a beacon of scientific ingenuity and human resilience against the formidable challenges of neurodegenerative disease.

Subject of Research: Gene editing for treating neuronal intranuclear inclusion disease through excision of expanded GGC repeats in NOTCH2NLC

Article Title: Precise excision of expanded GGC repeats in NOTCH2NLC via CRISPR/Cas9 for treating neuronal intranuclear inclusion disease

Article References:
Xie, N., Pan, Y., Tong, H. et al. Precise excision of expanded GGC repeats in NOTCH2NLC via CRISPR/Cas9 for treating neuronal intranuclear inclusion disease. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68385-5

Image Credits: AI Generated

One of the most compelling examples of this technological leap is seen in the application of rAAV8 vectors to deliver the tiny rAAV8 vectors encoding CasMINI_v3.1/ge4.1 that target the Nr2e3 gene, leading to substantial transduction in retinal cells. In a specific study involving RhoP23H/+ mice, which serve as a model for retinitis pigmentosa (RP), researchers recorded transduction efficiencies exceeding an impressive 70%. Post-administration, notable improvement in cone photoreceptor function was observed, which was critical in validating the capability of these compact Cas systems to facilitate effective genome editing. The implications of such enhancements are profound, especially considering the societal implications of restoring vision potentially lost due to inherited retinal diseases.

Another trailblazing innovation includes the use of rAAV9 vectors to deliver the compact adenine base editor Nme2-ABE8e, derived from Neisseria meningitidis. This specific application targets and corrects mutations within the Fah gene responsible for hereditary tyrosinemia type 1 (HT1). While the overall editing efficiency may seem modest at 0.34%, what’s remarkable is that it managed to restore 6.5% of FAH+ hepatocytes—above the therapeutic threshold required for meaningful restoration of normal function in affected cells. This example showcases the promising potential of employing all-in-one rAAV-mediated approaches in clinical settings for complex genetic disorders, effectively harnessing the power of genetic engineering to mend the underlying causes of diseases.

The advancements in delivering CRISPR systems using rAAV vectors establish a noteworthy foundation for the ongoing development of gene-editing therapies. With dual rAAV vectors that separate the Cas9 protein and guide RNAs onto different vectors, researchers are overcoming the previously limiting size issue associated with single rAAV vectors. This dual-vector delivery approach has resulted in the successful and safe restoration of full-length dystrophin expression within treated muscles, case numbers that signify a breakthrough in the treatment of disorders such as Duchenne muscular dystrophy. The therapeutic implications of this model demonstrate its broader applicability in treating genetic defects associated with large genomic alterations.

Despite these successes, the challenge remains to ensure efficient co-transduction of the dual vectors into target cells. The effectiveness of genome editing hinges largely on the simultaneous delivery and successful co-administration of both rAAV vectors. Studies continue to explore innovative strategies to ensure that both the nuclease and gRNA reach their intended destination together, maintaining high editing efficiency and efficacy. To this end, advancements in vector design and modulation strategies are gaining momentum, revealing their therapeutic potential in managing conditions that are associated with larger genome alterations.

In a further evolution of vector technology, the development of protein trans-splicing rAAV vectors is rapidly becoming a frontier for addressing CRISPR delivery limitations. By employing inteins—self-catalyzing protein elements capable of splicing—they can code for split Cas proteins that reassemble into a functional enzyme. In the context of treatments, this strategy has demonstrated therapeutic efficacy in preclinical studies for conditions such as amyotrophic lateral sclerosis, where introducing a split cytidine base editor improved neurologic function. Furthermore, the versatility of rAAV vectors enables the flexibility of selecting split sites, facilitating a renewed approach to gene therapy.

A notable aspect of the protein trans-splicing rAAV system involves its capacity to facilitate efficient prime editing—a method that offers potentially more precise editing compared to traditional CRISPR systems. Recent studies have highlighted its application in mouse brain and liver models. The success of this method underlines the multifaceted capabilities of rAAV vectors and suggests ongoing refinement to enhance editing precision across various tissue types. With the ability to effect corrections at deeper genetic levels, this evolution serves to better address a spectrum of genetic disorders.

Moreover, RNA trans-splicing rAAV vectors represent an additional layer of innovation, offering new possibilities for CRISPR delivery systems. Instead of relying on protein-level reconstitution, these vectors facilitate reconstitution at the RNA level, thereby eliminating concerns around misfolded protein intermediates. This new approach paves the way for flexibility in selecting split sites, which—when coupled with successful vector delivery—yields promising results across diverse tissues. Clinical applications of this technology encapsulate the continuing evolvement of gene-editing solutions and their real-world applicability, providing optimism for future gene therapeutic endeavors.

As evidence mounts confirming the reliability and versatility of these mRNA trans-splicing vectors, their application across different tissues usher significant advancements in genetic treatment capabilities. Noteworthy outcomes achieved through this method have included restoring visual function in models of retinitis pigmentosa and attaining substantial levels of gene editing in various organs. Each proof-of-concept study further exemplifies the clinical potency of mRNA trans-splicing systems, underscoring potential applications in treating genetic defects across broad contexts.

Investigators are acutely aware that the future of gene therapy relies heavily on optimizing these intricate mechanisms within rAAV vectors. In a pivotal development known as REVeRT (reconstitution via mRNA trans-splicing), researchers are leveraging RNA trans-splicing technology to provide more efficient delivery channels for CRISPR components. This model effectively enables rAAV vectors to transcript their respective pre-mRNA into mature gene-editing proteins, enhancing function and potency across patient populations. The REVeRT system has demonstrated a higher efficiency by avoiding reliance solely on ITR-mediated concatemer formation, marking an exciting evolution in therapeutic delivery systems.

The combination of continued exploration into compact Cas proteins, innovative vector design, and efficient reconstitution pathways collectively forms a formidable response to the long-standing challenges in CRISPR-mediated gene therapy. As the research landscape progresses, bridging theoretical advancements with practical clinical applications brings tangible hope for numerous genetic disorders. Advancements made through these technologies are not solely reshaping genetic engineering; they are catalyzing the future of medicine itself, with the potential to revolutionize how we approach complex diseases. Ultimately, the present breakthroughs signal the dawn of a new era in genetic therapy, where the seamless integration of innovative methodologies promises a brighter future for individuals grappling with genetic afflictions.

The methods and technologies developed over recent years are thus not mere theoretical constructs. They represent a pivotal moment in the quest for effective genetic interventions, heralding promising pathways toward treating disease and improving health outcomes. The ongoing efforts underscore the necessity for continued investment in this field, as each breakthrough enhances our understanding of gene editing possibilities, opening doors for future exploration in complex genetic landscapes. In this light, the convergence of compact nucleases and cutting-edge delivery systems is shaping the next generation of gene therapies tailored specifically to the needs of patients, paving the way for durable and effective solutions in molecular medicine.

Subject of Research: Gene editing with rAAV vectors using compact nucleases for therapeutic applications.

Article Title: Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery.

Article References:

Gil, JS., Lee, S. & Koo, T. Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery.
Gene Ther (2025). https://doi.org/10.1038/s41434-025-00573-2

Image Credits: AI Generated

DOI: 12 November 2025

Keywords: CRISPR, rAAV vectors, gene therapy, genome editing, compact nucleases, trans-splicing technology.

Oral squamous cell carcinoma remains a formidable clinical challenge worldwide due to its aggressive nature, high recurrence rates, and limited responsiveness to conventional modalities such as chemotherapy and radiation. Oncolytic viruses, including oHSV-1, have emerged as a promising therapeutic strategy by selectively infecting and lysing tumor cells while sparing normal tissues, thereby offering a targeted approach with minimized systemic toxicity. However, the variable effectiveness of oHSV-1 in OSCC highlights the urgent need to unravel the molecular determinants that govern viral resistance to harness the full potential of this modality.

The investigators implemented a comprehensive CRISPR/Cas9 loss-of-function screen across OSCC cell lines to systematically identify genes that modulate cellular response to oHSV-1 infection. This unbiased approach involved transducing a genome-scale sgRNA library into OSCC cells, followed by infection with oHSV-1. Cells that survived viral oncolysis were sequenced to identify enriched gene knockouts conferring resistance or sensitivity. Among the top hits, SUV39H2 emerged as a central player, underscoring the enzyme’s role in shaping viral resistance phenotypes.

SUV39H2, a member of the SET domain-containing family of histone methyltransferases, is known to catalyze the trimethylation of histone H3 on lysine 9 (H3K9me3), an epigenetic mark associated with heterochromatin formation and gene silencing. The study highlights that increased SUV39H2 activity leads to modifications in chromatin structure that suppress the expression of host factors crucial for effective oHSV-1 replication and oncolysis. This epigenetic repression creates a cellular environment less permissive to viral propagation, thereby enabling tumor cells to evade the cytolytic effects of the oncolytic virus.

Further mechanistic investigations revealed that depletion of SUV39H2 sensitizes OSCC cells to oHSV-1-induced cell death, markedly enhancing viral replication and oncolytic efficacy. Conversely, overexpression of SUV39H2 correlated with diminished viral spread and reduced tumor cell killing. These reciprocal effects confirm the enzyme’s dual role as a gatekeeper of viral resistance. The findings suggest that targeting SUV39H2 pharmacologically or via gene-silencing strategies could potentiate oHSV-1 therapy, shifting the paradigm toward more effective combinatorial treatments.

The research team also delved into transcriptomic analyses to elucidate downstream gene networks affected by SUV39H2-mediated histone methylation. Data demonstrated that SUV39H2 suppresses antiviral response genes and interferon signaling pathways, which paradoxically can both facilitate and hinder viral infection depending on the cellular context. The intricate balance governed by SUV39H2 points to a sophisticated epigenetic circuitry that modulates host-virus interactions, revealing vulnerabilities that can be exploited therapeutically.

Importantly, the study’s translational implications are significant, as SUV39H2 expression levels could serve as a predictive biomarker to stratify OSCC patients who are likely to benefit from oHSV-1 treatment. By integrating CRISPR screening insights with clinical data, the research underscores a precision medicine approach to tailor oncolytic virotherapy, ultimately improving patient outcomes. Moreover, the epigenetic nature of SUV39H2’s regulation hints at the possibility of using small molecule inhibitors to transiently modulate chromatin states and enhance viral susceptibility.

The researchers emphasize that this work lays a foundational framework not only for OSCC but potentially for other solid tumors where oncolytic virus therapy faces resistance challenges. Given the conserved role of chromatin modifiers like SUV39H2 across cancer types, this discovery invites broader application and encourages the exploration of epigenetic drugs as adjuvants to virotherapy. The combination of epigenetic modulation with viral oncolysis could usher in a new generation of cancer treatments characterized by synergistic efficacy and nuanced control of tumor biology.

By employing cutting-edge CRISPR genome editing in an integrated systems biology approach, the study exemplifies the power of high-throughput functional genomics to unravel complex oncogenic resistance mechanisms. The authors note that future investigations will focus on in vivo validation of SUV39H2’s role in tumor models and the development of targeted inhibitors to assess safety and combinational therapy potential. Such studies will be crucial to transition these mechanistic insights from bench to bedside.

Furthermore, the elucidation of SUV39H2’s impact on the tumor microenvironment remains an intriguing avenue. Since epigenetic enzymes can influence immune modulation, the interplay between SUV39H2 activity, immune cell infiltration, and antiviral immunity warrants comprehensive exploration. Enhancing our understanding of how epigenetic regulation affects immune evasion mechanisms could provide a dual benefit in optimizing both virotherapy and immunotherapy strategies for OSCC.

The innovation encapsulated in this research epitomizes the burgeoning interface between epigenetics and virology in the cancer therapeutics landscape. It challenges established notions that viral resistance is dominated solely by cell-intrinsic antiviral pathways, spotlighting chromatin architecture as an unexpected but vital determinant. The insights derived advocate for an integrative therapeutic design incorporating genetic, epigenetic, and virologic factors, potentially revolutionizing treatment paradigms for refractory cancers.

Given the global burden of oral squamous cell carcinoma and the pressing need for effective therapies, this research injects fresh optimism into the field. The identification of SUV39H2 as a modulator of oHSV-1 resistance paves the way for rational drug development and personalized medicine applications. As clinical trials for oncolytic viruses expand, incorporating biomarkers such as SUV39H2 expression might refine patient selection and therapeutic regimens, enhancing success rates.

In summary, the study stands as a testament to the transformative potential of CRISPR/Cas9 screening in oncology research, offering tangible targets to overcome therapeutic resistance. By unmasking the epigenetic gatekeeper SUV39H2, the authors provide a molecular key to unlock enhanced viral oncolysis in oral squamous cell carcinoma. This breakthrough heralds a promising chapter in oncolytic virotherapy, one poised to accelerate advances against stubborn malignancies through the marriage of genetic engineering and epigenetic modulation.

The evolving narrative of cancer treatment continues to affirm the importance of multidisciplinary innovation, and this work exemplifies the confluence of cutting-edge genomics, molecular biology, and viral therapeutics. As the field moves forward, such integrated approaches will be indispensable to outmaneuver cancer’s adaptive resilience and achieve durable cures.

Subject of Research: Oral squamous cell carcinoma resistance to oncolytic herpes simplex virus 1 (oHSV-1) mediated by epigenetic regulation.

Article Title: CRISPR/Cas9 screening identifies SUV39H2 as a key regulator of oHSV-1 resistance in oral squamous cell carcinoma.

Article References:
Qiu, M., Zhang, Q., Li, R. et al. CRISPR/Cas9 screening identifies SUV39H2 as a key regulator of oHSV-1 resistance in oral squamous cell carcinoma. Cell Death Discov. 11, 402 (2025). https://doi.org/10.1038/s41420-025-02702-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02702-7

The pioneering work, spearheaded by Professor Jeongbin Park and co-first authors Abyot Melkamu Mekonnen and Kang Seong, introduces an innovative computational platform that acknowledges that CRISPR off-target activity is not a one-size-fits-all phenomenon but varies substantially based on allele-specific sequence context. This insight forms the foundation of Variant-aware Cas-OFFinder, which accepts phased single-sample Variant Call Format (VCF) files containing detailed genetic variant information. The tool reconstructs allele-specific genome sequences by incorporating single nucleotide polymorphisms (SNPs) along with insertions and deletions from the individual’s genotype data. This haplotype-level reconstruction enables the algorithm to perform off-target site predictions that reflect the unique genomic landscape of each allele, thereby offering unprecedented precision in identifying potential CRISPR editing risks.

While existing bioinformatics tools such as Cas-OFFinder and CRISPRitz provide rapid scanning of reference genomes for potential off-target sites, their reliance on canonical reference sequences inevitably overlooks individual-specific variants that may generate novel off-target loci or mask others. Variant-aware Cas-OFFinder transcends this limitation by enabling variant-aware scanning. By considering the full spectrum of small variants, the tool identifies off-target sites attributable specifically to insertions and deletions, which are often neglected in prior analyses. This significantly elevates the sensitivity and specificity of off-target prediction, setting a new standard for computational genome editing safety assessments.

Equipped with robust GPU acceleration compatibility, Variant-aware Cas-OFFinder supports resource-intensive haplotype-level analyses while maintaining practical computational efficiency. The tool currently accommodates genetic data from an impressive range of 557 species and supports 40 Protospacer Adjacent Motif (PAM) types, showcasing remarkable versatility across biological domains. This extensibility opens avenues for personalized genome editing applications not only in human health but also in agriculture and environmental sciences, where accurate off-target prediction tailored to diverse species and cultivars is vital.

Critically validating their tool, the Pusan National University team applied Variant-aware Cas-OFFinder to human and sweet pepper (Capsicum annuum) genomes, utilizing both public datasets and cultivar-specific sequencing information. In human samples, the analysis uncovered potential off-target sites on chromosome 10 that were absent from the standard human reference genome, highlighting the necessity of including personal genomic variation for reliable CRISPR design in clinical contexts. In the agricultural context, the tool identified allele-specific off-targets within sweet pepper cultivars, demonstrating how such haplotype-aware analyses can facilitate precision breeding strategies and accelerate the development of improved plant varieties with minimized genomic risks.

Although Variant-aware Cas-OFFinder presently does not handle large structural variants — which remain a challenging frontier due to their complexity and length — its focus on small variants already fills a crucial void in current methodologies. The tool’s flexible customization via YAML configuration files caters to advanced users aiming to tailor off-target detection parameters to their specific research requirements, enhancing its accessibility and utility across a broad user base.

Fundamental to the philosophy of this project is the assertion from Prof. Park that genome editing must be as individualized as the very genetic material it seeks to modify. This resonates with emerging trends toward personalized medicine, where therapeutic interventions increasingly take into account patient-specific genetic landscapes. By fostering precise off-target prediction at the haplotype level, Variant-aware Cas-OFFinder offers a technological foundation for safer and more ethical clinical genome editing, reducing risks of unintended mutagenesis that could lead to oncogenic or other adverse outcomes.

The user experience has been carefully designed to accommodate a broad spectrum of users. Scientists and clinicians can access Variant-aware Cas-OFFinder either through a user-friendly web interface for quick analyses or via a command-line version that integrates seamlessly with bioinformatics pipelines. To promote transparency and community-driven development, all related source code, benchmarking tools, and example datasets have been made openly available on GitHub and Zenodo repositories, aligning with open science principles.

Balancing computational complexity with predictive accuracy, the haplotype-level analyses implemented by Variant-aware Cas-OFFinder may introduce modest performance overheads compared to earlier tools limited to reference genomes. However, this trade-off is justified by the substantial increase in result fidelity and the capability to reveal personalized off-target profiles otherwise obscured in traditional analyses. This paradigm shift embraces the genomic intricacies of individuals rather than forcing them into a standardized mold.

The implications of this tool extend beyond academic research, heralding transformative possibilities in therapeutic genome editing. CRISPR therapies aiming to correct deleterious mutations in patients’ cells can now be refined to avoid off-targeting that may jeopardize patient safety. Similarly, agricultural biotechnologists can harness these insights to safely engineer crop genomes, tailoring modifications to specific cultivars’ genetic backgrounds and thus enhancing both efficacy and regulatory compliance.

As genome editing technologies continue to mature, the integration of variant-aware computational tools like Cas-OFFinder will be indispensable for minimizing off-target effects and realizing the full potential of precision medicine and sustainable agriculture. This innovation from Pusan National University marks a vital step towards the ultimate goal of personalized genome engineering that respects individual genetic uniqueness while maximizing safety and efficacy.

In summary, Variant-aware Cas-OFFinder represents a major advance in the computational genomics field by offering a haplotype-resolved, variant-informed approach to CRISPR off-target prediction. Its development addresses longstanding limitations of previous tools, builds a robust platform adaptable to hundreds of species, and delivers critical insights for both biomedical and agricultural genome editing applications. As the scientific community embraces such sophisticated tools, the promise of CRISPR as a truly precise genome engineer comes closer to fruition.

Subject of Research: Not applicable

Article Title: Variant-aware Cas-OFFinder: web-based in silico variant-aware potential off-target site identification for genome editing applications

News Publication Date: 8-May-2025

References: DOI: 10.1093/nar/gkaf389

Image Credits: Credit: Professor Jeongbin Park from Pusan National University, Korea

Keywords: CRISPRs, Genome editing, Computational biology, Bioinformatics, Genetic variation, Technology, Health and medicine, Plant genomes, Haplotypes